Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma Plc Cl A

< Previous 1 2 3 4 5 6 7 Next >
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
Via The Motley Fool
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Insights Ahead: Royalty Pharma's Quarterly Earnings
Via Benzinga
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
Royalty Pharma Reports Third Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
From Royalty Pharma plc
Via GlobeNewswire
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire. 
Via The Motley Fool
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
2 No-Brainer Dividend Stocks to Buy With $100 in October
With their high yields and strong underlying businesses, these stocks are hard to pass up. 
Via The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Now could be a great time to scoop up three stocks trading way below their previous peaks. 
Via The Motley Fool
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
Via Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Third Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.